{"prompt": "['Interferon beta-la', 'MESTRE-MS Study', 'EMR200136_597', 'Non-Interventional Study Protocol', 'Study Protocol Number', 'EMR200136_597', 'Title', 'A Phase IV, prospective, multicenter, open label,', 'uncontrolled, non-interventional, single arm study to', 'measure treatment satisfaction of multiple sclerosis (MS)', 'patients on Rebif after discontinuing initial first-line', 'treatment', 'Study acronym/Short title', 'MESTRE-MS (MEasuring Satisfaction of Treatment with', 'REbif after initial treatment of MS)', 'Protocol version identifier', 'Version 2.0', 'Date of last version of 07 Oct 2016', 'protocol', 'Replaces Study Protocol Version 1.0/20 May 2016', 'Version', 'Active substance', 'International Nonproprietary Name (INN): Interferon', 'beta-la;', 'Pharmacotherapeutic Group: Immunostimulants;', 'Anatomical Therapeutic Chemical (ATC) Code: LO3AB07', 'Medicinal product', 'Rebif', 'Marketing authorisation', 'Merk Serono Europe Limited', 'holder (MAH)', 'Research question and', 'The purpose of this study is to investigate treatment', 'objectives', 'satisfaction of MS patients, who have discontinued first-line', 'MS oral or injectable MS medication, and have initiated', 'treatment with Rebif.', 'Primary objective', 'To determine the level of treatment satisfaction as', 'measured with the Treatment Satisfaction Questionnaire', 'for Medication Version II (TSQM V II), in relapsing', 'remitting MS (RRMS) patients who have discontinued', 'their initial oral or injectable MS treatment, and have', 'initiated treatment with Rebif.', 'Secondary objectives', 'To evaluate the change in annualized relapse rate (ARR)', 'in patients changing from initial oral or injectable forms', 'of treatment to Rebif', 'CONFIDENTIAL', '1/60', 'INFORMATION', 'M']['Interferon beta-la', 'MESTRE-MS Study', 'EMR200136 597', 'To assess therapy adherence to Rebif', 'To determine the change in quality of life with Multiple', 'Sclerosis International Quality of Life Questionnaire', '(MusiQoL) between Baseline, Month 6 and Month 12', 'To document the reasons for discontinuation of initial', 'MS treatment', 'To evaluate the potential correlations between the', 'following measurements: TSQM v II, ARR, adherence,', 'reasons for discontinuation, MusiQoL and TSQM V II', 'subscales', 'To assess the difference between TSQM V II subscales', 'between Baseline, Month 6 and Month 12.', 'Countries of study', 'The study will be conducted in approximately 33 centers', 'across Europe region in Belgium, Switzerland and the', 'Netherlands.', 'Author', 'PPD', 'Medical Writer', 'PPD', 'PPD', 'PPD', 'Tel: PPD', 'Fax', 'PPD', 'Email: PPD', 'MAH', 'Merk Serono Europe Limited,', '56, Marsh Wall,', 'London E14 9TP,', 'United Kingdom.', 'MAH contact person', 'PPD', '- Confidential -', 'This document is the property of Merck KGaA, Darmstadt, Germany, or one of its affiliated companies. It is intended', 'for restricted use only and may not- in full or part- be passed on, reproduced, published or used without express', 'permission of Merck KGaA, Darmstadt, Germany or its affiliate. Copyright\u00a92016 by Merck KGaA, Darmstadt,', 'Germany or its affiliate. All rights reserved.', 'CONFIDENTIAL', '2/60', 'INFORMATION', 'M']['Interferon beta-la', 'MESTRE-MS Study', 'EMR200136_597', '1', 'Table of Contents', '1', 'Table of Contents', '3', '2', 'List of Abbreviations', '6', '3', 'Responsible Parties', '7', '3.1', 'Responsibilities of the Investigator', '10', '4', 'Abstract', '11', '5', 'Amendments', '17', '6', 'Milestones', '17', '7', 'Rational and Background', '18', '8', 'Research Question and Objectives', '21', '8.1', 'Primary Objective', '21', '8.2', 'Secondary Objectives', '21', '8.3', 'Other Objectives', '21', '9', 'Research Methods', '21', '9.1', 'Study Design', '21', '9.1.1', 'Design Overview', '22', '9.1.2', 'Endpoints', '23', '9.2', 'Setting', '24', '9.2.1', 'Study Population', '24', '9.2.2', 'Definition of Study Cohorts and Description of Treatments', '25', '9.2.3', 'Observation Period', '26', '9.2.4', 'Frequency of Assessments', '26', '9.2.5', 'Withdrawal from the Study', '28', '9.3', 'Variables', '29', '9.4', 'Data Source', '31', '9.5', 'Study Size', '31', '9.6', 'Data Management', '31', '9.7', 'Data Analysis', '32', '9.7.1', 'Analysis Sets', '32', '9.7.2', 'Derived and Transformed Data', '32', '9.7.3', 'Statistical Methods', '33', 'CONFIDENTIAL', '3/60', 'INFORMATION', 'VI']\n\n###\n\n", "completion": "END"}